Objective: To examine health-related quality of life, we investigated the effect of adjuvant chemotherapy regimens on utility scores assessed by the EuroQoL-5D (EQ-5D) instrument in a randomized, controlled trial for breast cancer patients after surgery. We also investigated the relationship between Functional Assessment of Cancer Therapy (FACT) scale scores and EQ-5D utilities. Methods: Patients were randomly assigned to the following four chemotherapy regimens: four cycles of anthracycline followed by paclitaxel (ACP), four cycles of anthracycline-containing regimens followed by docetaxel (ACD), eight cycles of paclitaxel (PTX), and eight cycles of docetaxel (DTX). Of 1060 registered, the first 300 consecutive patients were included in the current utility study. Utility scores were assessed using the EQ-5D instrument at baseline; cycles 3, 5, and 7; 7 months; and 1 year. We also evaluated the correlation between these scores and FACT-G, -B, and -Taxane scores at each time point. Results: Utility scores were significantly lower in the DTX group than in the ACP and ACD groups. Mean utility scores in the DTX group were lowest at 7 months and tended to remain low for a long time. The combined anthracycline followed by taxane group had significantly higher utility scores that the taxane-alone group, with no significant difference depending on the type of taxane. Only the FACT-G social/family well-being subscale had no relationship with EQ-5D responses and utility scores. Conclusions: Although the regimens in this study were similar in that they included taxane, the mean utility scores and longitudinal patterns of utility scores were different among regimens.
Introduction
In Japan, the number of patient deaths due to breast cancer is increasing, whereas breast cancer mortality has generally decreased since the 1990s in Europe and the United States [1] . In 2007, the death toll from breast cancer in Japan was estimated at 12,000 persons per year, and the age-adjusted mortality was 11.9 per 100,000 persons, making breast cancer second to colorectal cancer as leading causes of death due to malignant neoplasms in women [2] . Decreasing deaths due to breast cancer is one of the most important women's public health issues.
For increasing numbers of women with breast cancer, adjuvant combination chemotherapies are being used to prevent microscopic metastasis. Many kinds of chemotherapy regimens have been developed in the past two or three decades. Anthracyclinebased regimens (doxorubicin or epirubicin) have proved to be superior to CMF (cyclophosphamide, methotrexate, and fluorouracil) [1] and are primarily used as adjuvants to standard chemotherapy in breast cancer patients. Taxane (paclitaxel or docetaxel) [3, 4] , one of the most widely used anticancer drugs, is also being used in adjuvant breast cancer patients. Meta-analysis of 13 studies (N ϭ 22,903) shows that taxanes, in combination or in sequence with anthracycline (AC)-based regimens, significantly improve disease-free survival (DFS) and overall survival of early breast cancer patients [5] . The pooled hazard ratios estimated by the metaanalysis were 0.83 (95% confidence interval [CI] 0.79 -0.87) for DFS and 0.85 (95% CI 0.79 -0.91) for overall survival . The efficacy, however, of taxane alone regimens without AC or cyclophosphamide is not known.
The National Surgical Adjuvant Study of Breast Cancer-02 (N-SAS BC 02) was conducted to compare two general protocols for treating node-positive breast cancer patients: 1) four cycles of ACcontaining regimens followed by four cycles of taxane and 2) eight cycles of taxane. Because AC regimens have a risk of causing lifethreatening cardiotoxicity [6] , they are contraindicated in patients with abnormal cardiac function. If taxane regimens are not inferior to AC-based regimens, the use of taxane alone as an alternative chemotherapy might be increased.
Nevertheless, it is possible that administration of taxane will cause serious adverse events, such as peripheral neuropathy. It is well-known that taxane-induced peripheral neuropathy occurs in proportion to the dose level and cumulative dose. Even if eightcycle taxane regimens have a nearly identical efficacy as AC-based regimens, such adverse events may decrease health-related quality of life (HRQOL) or expected quality-adjusted life years (QALYs) [7] . To examine the HRQOL, we included measurement by the Functional Assessment of Cancer Therapy (FACT) scale [8, 9] and EuroQoL-5D (EQ-5D) [10, 11] as secondary end points in N-SAS BC 02 trial. EQ-5D scores are also intended for use in the economic evaluation of eight-cycle taxane regimens. In this article, we report on utility scores of early breast cancer patients measured by EQ-5D and the relationship between EQ-5D and FACT scale scores.
In addition, there are few reliable data on utility scores of breast cancer patients in Japan. Unfortunately, it is rare for longitudinal HRQOL or utility scores to be collected in Japanese prospective clinical trials. We planned to prospectively evaluate utility scores during treatment as well as 1 year post-treatment in breast cancer patients receiving four different types of taxanecontaining adjuvant chemotherapy.
Methods

Patients
The N-SAS BC 02 trial included the following eligibility criteria: age 18 to 70 years, node-positive disease, no metastasis (stages I-IIIA), no previous hormone or chemotherapy, and an Eastern Cooperative Oncology Group performance status of 0 -1 [12] . Patients who were both estrogen receptor and progesterone receptor positive were excluded. The study protocol of N-SAS BC 02, however, was amended to permit the enrollment of both hormonepositive patients from June 2003. Written informed consent was required from all patients before study enrollment, and the study was approved by the institutional review boards of the participating centers.
Study design and treatment protocols
Based on the 2 ϫ 2 factorial design, the 1060 eligible patients were randomly assigned to receive one of the following four regimens: a) four cycles of AC-containing regimens (doxorubicin 60 mg/m 2 or epirubicin 75 mg/m 2 ϩ cyclophosphamide 600 mg/m 2 every 3 weeks Randomization was performed centrally, and we used the minimization method to balance treatment allocation according to nodal status, surgical procedure, hormone receptor status, HER2 status, tumor diameter, and medical center. The first 300 consecutive patients of the randomized patients from the N-SAS BC 02 trial were included in this HRQOL study (Fig. 1) . The primary end point was DFS, defined as time from randomization to the first occurrence of any of the defined events. HRQOL and cost-effectiveness were two of the secondary end points.
HRQOL assessment
HRQOL was assessed by the Japanese version of the FACT-G scale [8, 9] , FACT-B scale [13] , FACT-Taxane scale [14] , and EQ-5D. The FACT-G scale is a 27-item patient self-reporting scale that has a total score (0 -108, with 108 for perfect functioning) that consists of four subscales (physical well-being [PWB], social/family well-being [SFWB], emotional well-being [EWB], and functional well-being [FWB] ). The FACT-B and FACT-Taxane scales are subscales for breast cancer and toxicity of taxane, respectively. The total scores on FACT-B and FACT-Taxane scales can be obtained by adding these subscores to total score of FACT-G (144 and 172 for perfect functioning). The EQ-5D has five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. There are three levels in each dimension, and patient responses to the EQ-5D can be converted to utility scores (0 -1, where 1 means perfect health in principle) [11] . This five-dimension descriptive system can evaluate 243 (3 5 ϭ 243) different health states. We performed baseline assessments of the FACT-G, -B, and -Taxane scales and the EQ-5D between the time of patient random assignments and the start of chemotherapy. Follow-up assessments were performed before administration of chemotherapy at cycles 3, 5, and 7; 7 months; and 1 year after starting adjuvant chemotherapy.
.
Statistical analysis
We calculated descriptive statistics for HRQOL at predetermined time points. In the case that one or more of the five EQ-5D responses were not obtained, we treated utility scores at this time point as missing values. Sample size of HRQOL population in N-SAS-BC 02 trial was not based on the statistical consideration; however, when effect size of FACT-G was 10-point and SD of the FACT-G scale score was 15, 75 patients in each group were needed. To detect differences in utility scores among chemotherapy regimens, longitudinal utility scores from EQ-5D were analyzed based on a linear mixed model [15] using the MIXED procedure in SAS 9.1 (SAS Institute, Cary, NC). Utility scores were analyzed by the model with the baseline scores as the covariate and group, time, and the interaction of time and group as fixed effects. The analysis used restricted maximum likelihood estimation [16] and a compound symmetry structure (an unstructured covariance structure was also applied as part of a sensitivity analysis). First, there were four different chemotherapy regimen groups. Second, patients in the ACP and ACD groups were pooled as the AC followed by taxane group, whereas those in the PTX and DTX groups were analyzed as the taxane-alone group. In the same way, the ACP and PTX groups were combined into the paclitaxel group, and the ACD and DTX groups were combined into the docetaxel group. In addition, to examine the influence of demographic and background factors on utility scores, we used another model that included additional variables such as age, type of hormone receptor, HER2 receptor status, surgery, number of positive lymph nodes, and tumor size. Statistical significance for all analyses was defined as P Ͻ 0.05 (two sided). To examine the relationship between HRQOL instruments, we calculated a correlation matrix between the EQ-5D (response to five questions and utility score) and FACT (FACT-G, -B, -Taxane, and FACT-G subscales) scale scores based on the Spearman rank correlation coefficient.
Results
Study population
Between November 2001 and May 2003, 300 patients were enrolled at 64 centers in Japan: 74 patients were randomly assigned to the ACP group, 75 to the ACD group, 76 to the PTX group, and 75 to the DTX group. Because there were no HRQOL data for one patient in the PTX group (withdrawal of consent), the patient was excluded from HRQOL population. The baseline characteristics of 299 patients are shown in Table 1 . These characteristics were not different from the entire intent-to-treat (ITT) population; with the exception of hormone receptor status (39.1% patients were positive in the QOL population and 62.5% in the ITT population). This is because protocol amendment permitted patients with both estrogen receptor-and progesterone receptor-positive cancer to enroll in the N-SAS BC 02 trial. The median age of the 299 patients was 53 years. More than half of the patients had one to three positive nodes, and in approximately one fourth of patients, tumors were HER2 positive.
Response to the EQ-5D survey
The numbers and percentages of 299 patients completing the EQ-5D at cycles 3, 5, and 7; 7 months; and 1 year after initiation of treatment were 294 (98%), 287 (96%), 275 (92%), 262 (88%), and 228 (76%), respectively. The percentage of missing values (at least one of the five EQ-5D responses was blank) was approximately 2% at each time point, although the percentage at 1 year was a little high (6.1%). The pattern of missing values was not different among the four groups. 
Comparison of utility scores among groups
The mean utility scores and differences from baseline are shown longitudinally by group in Figure 2 . The results show that utility scores measured by the EQ-5D in the DTX group were lower than in other groups. In addition, the pattern of utility scores over time in the DTX group was different from those in the ACP, ACD, and PTX groups: the lowest score in the DTX group occurred at 7 months from the start of treatment, although utility scores of the other three groups were lowest at cycle 7 or earlier.
The analysis showed there were significant differences in the interaction between time and group and group effects (P values were 0.0061 and 0.0002, respectively; Table 2 ). Compared with the DTX group, the utility scores in the ACP and ACD groups were significantly higher (P values were 0.0048 and Ͻ0.0001, respectively), but those in the PTX group were not significantly different (P ϭ 0.269). Least squares means of utility scores at each time point are presented in Table 3 .
The utility scores of the combined AC followed by taxane group (ACP and ACD groups) were significantly higher than the combined taxane-alone group (PTX and DTX groups) (difference ϭ 0.054, P Ͻ 0.0001; Table 2 ). On the other hand, there were no significant differences between the combined paclitaxel group (ACP and PTX groups) and the combined docetaxel group (ACD and DTX groups) (difference ϭ -0.002, P ϭ 0.889; Table 2 ). These results did not change when using an unstructured covariance structure (not shown).
Results from the analysis that included background factors showed that only age influenced the utility scores (P ϭ 0.0396, coefficient ϭ -0.015/10 years). Other factors, such as type of hormone receptor, HER2 receptor status, surgery, number of positive lymph nodes, and tumor size, did not significantly relate to utility scores. In the AC followed by taxane group, some patients received epirubicin, not doxorubicin. We observed no significant difference when comparing the epirubicin regimen with doxorubicin (P ϭ 0.126).
Relationship between the EQ-5D and FACT scales
We calculated the correlation coefficients between the EQ-5D and the FACT-G, FACT-B and FACT-Taxane scales. Table 4 shows only the results at cycle 7 (the last time point during chemotherapy) and 1 year (the last time point), and other results had almost the same pattern of correlation coefficients. The FACT-G SFWB subscale score had no relationship with EQ-5D responses or utility score (almost all the correlation coefficients are Ͻ0.1), although other subscale scores and total scores were related at least to the utility score. We found similar relationships at all the time points. In addition, the self-care dimension of EQ-5D has little correlation with FACT-G, -B, -Taxane, and FACT-G subscale scores. On the other hand, there were strong correlations between the FACT-PWB subscale and utility scores and between the FACT-Taxane and utility scores. We also observed strong correlations (r Ͼ 0.6 for at least one time point) between the following FACT subscales and EQ-5D dimensions: a) FACT PWB subscale and pain/discomfort dimensions of the EQ-5D and b) FACT EWB subscale and the anxiety/pain dimension of the EQ-5D.
Discussion
Our analysis showed that the DTX regimen resulted in lower mean utility scores and a different pattern of utility scores over time from the ACP, ACD and PTX groups. We found that the only background factor that significantly influenced the utility score was patient age. There are not many articles on utility scores of adjuvant breast cancer patients measured by EQ-5D or other instruments. A review [17] of EQ-5D-based utility scores in cancer patients found that utility scores of breast cancer patients generally range from 0.7 to 0.8, which is consistent with our analysis.
According to the interim analysis of the N-SAS BC 02, the survival curve of the PTX group tended to be lower than that of the AC, anthracycline; ACD, four cycles of anthracycline-containing regimens followed by docetaxel; ACP, four cycles of anthracycline followed by paclitaxel; CI, confidence interval; DTX, eight cycles of docetaxel; PTX, eight cycles of paclitaxel; SE, standard error. * P Ͻ 0.05. Table 3 other three groups, and the taxane-alone group was not inferior to the AC followed by taxane group in terms of DFS (hazard ratio 1.26, 95% CI 0.99 -1.60, P ϭ 0.67). Docetaxel (75 mg/m 2 ) was superior to paclitaxel (175 mg/m 2 ) when given every 3 weeks in terms of DFS (hazard ratio 0.81, 95% CI 0.64 -1.03, P ϭ 0.08) [18] . Because the utility scores of the AC followed by taxane group were higher than the taxane-alone group, the AC followed by taxane regimen is possibly preferable in terms of QALYs. In addition, because utility scores of the docetaxel regimen were nearly equal to those of the paclitaxel regimen from our analysis, more QALYs can be obtained using the docetaxel regimen than the paclitaxel regimen.
Although the utility scores during chemotherapy decreased compared with baseline, the utility scores of all four groups recovered to at least baseline level at the 1-year time point. The influence of chemotherapy seems to disappear by 1 year from the start of chemotherapy. It is unclear why the utility scores of the DTX group were lower at this time point because the lowest utility score for this group was delayed compared with the other groups, but the toxicity of the DTX regimen may be greater and continue for a long time after completion of chemotherapy. Other than edema, there were no adverse events frequently observed in the DTX group. Grade 3 or 4 edema was seen in 13.3% of patients in DTX group (n ϭ 10), and only one patient in the ACD group experienced severe edema among the other groups. The utility scores of patients with edema (grade 1: 0.789, grade 2: 0.729, grade 3: 0.608 at 7 months) were lower than those without edema (0.824). This may have had on impact on the utility scores in the DTX group.
The correlation matrix showed that the FACT-G SFWB subscale had no relationship with EQ-5D responses and utility scores. This means that utility scores measured by the EQ-5D do not reflect social and family well-being. A similar result was reported by a study group in Singapore [19] . We found strong correlations between FACT-PWB subscale and utility scores and between FACTTaxane and utility scores. The correlation coefficient between FACT-PWB subscale and utility scores was greater than that between FACT-G total scale and utility scores because FACT-PWB includes questions similar to those of the EQ-5D; for example, "I am forced to spend time in bed" (GP7) and mobility, "I have pain" (GP4) and pain/discomfort, and "I feel ill" (GP6) and anxiety/depression. The significant correlation between FACT-Taxane and utility scores may suggest that the toxicity of taxane has a great influence on the utility scores.
The minimally important difference (MID) for the utility score measured by the EQ-5D is not necessarily clear. One study estimated the MID as 0.040 for the EQ-5D (US algorithm) and 0.082 for the EQ-5D (UK algorithm) [20] . Another study reported that the MID was 0.07 to 0.12 for EQ-5D (UK algorithm) and 0.06 to 0.09 for EQ-5D (US algorithm) in cancer patients [21] . Although the MID for Japanese patients has not been examined, the difference in utility score between ACD and DTX groups in this study was 0.077, which can be interpreted as meaningful according to these previously published criteria.
Patients who were asked to respond to the HRQOL instruments are part of a randomized population. Because they are the first 300 consecutive patients and were not selected using other criteria, we consider them an unbiased population from the ITT population. The proportion of hormone receptor-positive patients in the QOL population is lower than in the ITT population because of protocol amendment, but the percentages of other background factors are the almost same. The analysis shows that the status of hormone receptor does not significantly influence utility scores.
Our study examined longitudinal utility scores of breast cancer patients during and after four chemotherapy regimens in a randomized, controlled trial. Although the regimens in this study were similar in that they included taxane, the mean utility scores and longitudinal patterns of utility scores were different among the regimens.
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